03317nas a2200361   4500000000100000008004100001260004400042653002600086653001500112653001900127653002600146653001200172100001700184700001700201700001500218700001700233700001600250700001600266700001900282700001600301700001200317700001500329700001900344700001400363700001300377700003100390700001500421245014000436856004600576490000700622520231200629022001402941       2025                            d  bSpringer Science and Business Media LLC10aCommunicable Diseases10aInequality10aSocial housing10aSocioeconomic Factors10aLeprosy1 aTeixeira CSS1 aPescarini JM1 aSanchez MN1 aFerreira AJF1 aFiaccone RL1 aIchihara MY1 aFlores-Ortiz R1 aBrickley EB1 aCraig P1 aLeyland AH1 aKatikireddi SV1 aPenna MLF1 aPenna GO1 ade Cássia Ribeiro-Silva R1 aBarreto ML00aThe Minha Casa Minha Vida social housing programme and leprosy in Brazil: an analysis of the 100 Million Brazilian Cohort (2010–2015)  uhttps://pubmed.ncbi.nlm.nih.gov/40759946/0 v253 a<p><strong>Background</strong> Ensuring housing interventions can contribute to improved living conditions which are strong socioeconomic determinants of leprosy. We estimated the association between the social housing programme Minha Casa Minha Vida (MCMVP) and leprosy new cases.</p>

<p><strong>Methods</strong> We followed families registered in the 100 Million Brazilian Cohort linked with MCMVP receipt and nationwide registries of leprosy between 2010 and 2015. We used Cox regression weighted by stabilized inverse probability of treatment weighting (IPTW) to assess the hazard ratio (HR) for the effect of MCMVP on leprosy. Weights were obtained by propensity score using demographic and socioeconomic covariates at baseline. Sensitivity analyses were done considering potential delays to receiving MCMVP, municipality of residence population size and by controlling by the baseline risk of leprosy among potential recipients.</p>

<p><strong>Results</strong> We followed up 24,584,768 individuals, of which 618,883 (2.5%) were MCMVP recipients, and detected 8,874 new leprosy cases during the study period. Leprosy incidence was higher among MCMVP recipients (13.32/100,000 pyr; 95%CI = 11.45–15.49) compared to non-recipients (11.72/100,000 pyr; 95%CI = 11.47–11.97). MCMVP recipients had higher leprosy incidence (HR = 1.66; 95%CI = 1.34–2.06), compared to non-recipients. Point estimates were lower when considering a delay of 6 or 12&nbsp;months to moving into the new household (HR = 1.53; 95%CI = 1.20–1.95 and HR = 1.37; 95%CI = 1.05–1.78, respectively), in small/medium municipalities (≤ 300,000 inhabitants) (HR = 1.95; 95%CI = 1.51–2.52), and higher among individuals who subsequently became MCMVP beneficiaries before receiving the benefit (HR = 2.29; 95%CI = 1.93–2.72).</p>

<p><strong>Conclusions</strong> This study found a higher risk of leprosy associated with MCMVP that may reflect reverse causality. Our findings suggest the programme is, in fact, reaching the most vulnerable individuals, as intended in its objectives. Besides, the higher risk of leprosy among MCMVP beneficiaries even before receiving the benefit observed in sensitivity analysis may reflect residual confounding factors related.</p>
  a1471-2458